跳至主要内容
临床试验/NCT03343275
NCT03343275已完成不适用

Multicenter, Controlled and Randomized Clinical Trial to Evaluate the Combined Use of a Medical Device and a Food Supplement in the Control of Urinary pH in Patients With an Implanted Double Pigtail Stent

Devicare S.L.16 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2017年12月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
105
试验地点
16
主要终点
Incrustation Score

研究概览

简要总结

This study evaluates the effectivity in urinary pH Control and the prevention of calcification in Double J stent using a device combined with the intake of dietary supplements. Every patient will receive hygienic-dietary indications.

Patients will also take one out of the three dietary supplements regarded within the study (pH Up, pH Down and Cysteine) to control the adequate pH level, always following medical indications.

详细描述

Several studies have shown the importance of urinary pH Control (pHv) to determine the frequency of stent incrustation, this measure being a variable to be taken into account in the management of catheterized patients. However, the level of pHv is influenced by multiple factors, so its routine control is difficult to interpret. The nucleation pH (pHn) was described on 1999: the pH where the incrustation starts to form. In his study he observed that the pH of the patients who developed a stent blockage and the pH of those who were not very similar (7.46 and 7.38 respectively), but observed that the pHv of the patients who did not have incrustations was much lower and therefore had a much wider safety margin.

As already mentioned, pHv is influenced by different factors, but it is especially sensitive to diet. For this reason, hygienic and dietetic interventions (exercise, diet, fluid intake, etc.) are one of the preventive measures of incrustation of the stent of great utility, although its effectiveness is subject to patient adherence.

Lit-control®pH Down is a dietary supplement with an acidifying effect on urine, which helps in the prevention of complications arising from the alkalinization of urine. It contains L-methionine, phytin (calcium-magnesium phytate salt), zinc and vitamin A. The two active components in pHv acidification are L-methionine and phytin,while zinc and vitamin A increase the action of phytin. Specifically, zinc favors the affinity of its affinity for calcium phosphate and vitamin A prevents its degradation by alkaline phosphatase.

L-methionine is an essential amino acid that plays an important role in metabolic processes. It is normally acquired through food and absorbed in the small intestine to be metabolized in the liver via cysteine to sulphate and protons. Consequently, its administration produces a significant reduction of urinary pH.

According to the European Association of Urology (UAE), urinary acidification with L-methionine up to pH 5.8 - 6.2 is recommended as a therapeutic measure for calculations of struvite, calcium phosphate and ammonium urate at doses of 600- 1500 mg / day. This recommendation is based on the results observed in 1996, where an acidification of the pH of the urine of the patients was observed from 7.5 to 5.5 after the administration of 1500-3000 mg / day (3-6 capsules) of 500mg / day. Also in the study of Hesse 1999 a significant reduction in urinary pH was observed up to pH = 6.0 after the administration of a single dose of 1500 mg of L-methionine, maintaining this effect for 24h. In addition, a significant reduction was observed versus the control group in terms of the relative supersaturation for struvite and brushite in the urine of 24h. In another more recent study, the authors studied the circadian course of urinary pH after the administration of 1500 mg of L-methionine. They observed a strong decrease in urinary pH up to 2h after the administration of the amino acid that remained at significantly low levels for 8h, resulting in a pH level for 24h between 5.98 and 6.32. Therefore, in order to guarantee therapeutic doses of L-Methionine (1500mg / day), the Lit-control®pH Down regimen to follow would be equivalent to 3 capsules per day (500 mg / capsule).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years old
  • Patients which have been recently implanted a Double J stent (less than a week implant) or who have planned their implant and have been recommended with pH control to avoid incrustation/calcification.
  • Patients who accept their participation in the study and give their informed consent

排除标准

  • Patients with base pathologies wich , based on clinical criteria, aren´t sensitive about the study dietary supplement indications.
  • Patients which have programmed the stent extraction 3 weeks before base visit.
  • Uric and cystinuric patients which requires pH control different from the established study protocol .

研究组 & 干预措施

Experimental

Experimental

Dietary supplement : Lit-Control® pH Down

  • Pharmaceutical form: capsules
  • Administration : oral
  • Dose: 3 capsules/day.

• Sanitary product : Lit-Control® pH Meter

  • In vitro diagnosis sanitary product
  • Use:Urinary pH evaluation

干预措施: Lit control pHDown (Combination Product)

Placebo

Placebo Comparator

Placebo:

  • Pharmaceutical form: capsules
  • Administration : oral
  • Dose: 3 capsules/day.

• Sanitary product : Lit-Control® pH Meter

  • In vitro diagnosis sanitary product
  • Use:Urinary pH evaluation

干预措施: Lit control pHDown (Combination Product)

结局指标

主要结局

Incrustation Score

时间窗: 2 days

0 (No incrustation); 1(Sporadic incrustation less than 1-2 mm); 2 (Wide area calcifications more than 1-2 mm) ; 3 (Total obstruction)

Urinary pH level

时间窗: 2 times/day

Stent implant cause

时间窗: 2 months

Medical evaluation and diagnosis leading to stent implant

Self-control below values 6.2

时间窗: 2 times/day

次要结局

  • Anatomic alterations on the urinary system(2 months)
  • Previous uropathic obstructive incidence(2 months)
  • Date of past stent implants(2 months)
  • pH control: Total time(2 times/day)
  • Complications associated with stent implant(2 months)
  • Treatment adherence(2 months)
  • Stent extraction data(2 months)
  • Blockage risk factor(1 month prior intervention)
  • Date of stent extraction(2 months)
  • Type of previous stent(2 months)
  • 2 hours urine analysis :Fasting(2 hours)
  • Urine culture(48 hours)
  • Number of different symptoms associated with the previous calcification(2 months)

研究者

发起方
Devicare S.L.
申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验